Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors

NCT06054932 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: LK101 injection
DRUG: LK101 injection

Sponsor

Beijing Likang Life Science and Tech Co., Ltd.